Andy Lewis, Ph.D.Vice President of Pharmaceutical Sciences at Quotient Sciences
Andy Lewis, BPharm MAPS PhD is VP Pharmaceutical Sciences at Quotient Sciences where he leads a team of 120 scientists working on formulation development, clinical manufacturing and pharmaceutical analysis for clients’ drug product programs. Prior to this he was Director Novel Drug Delivery Technologies at Ipsen, where he had global responsibility for product development utilizing novel formulation technologies or drug delivery devices. He has also helped set up and grow two venture capital funded start ups, RegenTec and Critical Pharmaceuticals, where he led the development and commercialization of novel technologies in the fields of tissue engineering and drug delivery, taking them from concept into clinical development. He has a particular interest in overcoming drug delivery challenges, including sustained release and transmucosal delivery of proteins and peptides, and he has filed a number of patents in the field. He is a member of the Academy of Pharmaceutical Scientists of Great Britain, and has served on the board of directors of the Controlled Release Society (CRS) as Director-at-Large and most recently as Secretary.